Acid Phosphatase, Total and Prostatic
| Acid Phosphatase, Total and Prostatic | | | |
| Number | | 083386 |
| CPT | | 84060; 84066 |
| Synonyms | | AcP, Total and Prostatic ; Prostatic Acid Phosphatase, Colorimetric |
| Test Includes | | Total and prostatic acid phosphatase |
| Specimen | | Serum, frozen |
Volume | | 1 mL |
| Minimum Volume | | 0.25 mL |
| Container | | Red-top tube or gel-barrier tube |
| Collection | | Separate serum from clot promptly after blood collection. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested. |
| Storage Instructions | | Acid phosphatase at normal serum pH is very labile; therefore, freeze serum immediately to stabilize the enzyme. |
| Patient Preparation | | This enzyme is subject to circadian rhythms; for follow-up,
it should be drawn at the same time of day. |
| Causes for Rejection | | Hemolysis; icterus; lipemia; blood unprocessed for >1 hour
after collection; serum sample not frozen; plasma received |
| Reference Interval | | Total: 0.0-7.3 units/L; prostatic: 0.0-1.9 units/L |
| Limitations | | Elevations in 80% of individuals with metastatic prostate
cancer are related to the stage. PAP is not elevated in
early stage prostate disease. Currently, PAP has little
role in the early detection and management of prostate
cancer, having been replaced by the more sensitive PSA
test. PAP may have utility in limited cases. A high
preoperative PAP in a patient with clinically localized
prostate cancer suggests pathologically advanced stage
disease, and this patient may not be a good candidate for
surgical cure. PAP may also be used to monitor disease in
very rare cases where a tumor does not produce PSA. |
| Methodology | | Spectrophotometry |
| Additional Information | | Acid phosphatase (AcP) levels have historically been used
in diagnosing and monitoring prostatic cancer. Since AcP is
found in tissues besides the prostate (eg, bone),
concentrations of both the prostatic and nonprostatic forms
may be differentiated using tartrate. The activity of the
prostatic form of the enzyme is inhibited in the presence
of tartrate.
Elevations of AcP from nonprostatic origin would include
Paget disease, hyperparathyroidism, as well as primary or
metastatic neoplasms of the bone, all of which represent
AcP from osteoclastic activity. Increases have also been
observed in Gaucher disease, Neimann-Pick disease and
myelocytic leukemia. |
|